;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Avalanche skyrockets in trading debut

    Ophthalmic gene therapy play Avalanche Biotechnologies Inc. (NASDAQ:AAVL) jumped $10.99 (65%) to $27.09 on its first day of trading Thursday after raising $103 million through the sale of 6 million shares at $17 in an …

    Published on 7/31/2014
  • FINANCIAL NEWS: Bio Blast, Marinus, VBL take haircuts on IPOs

    Bio Blast Pharma Ltd. (NASDAQ:ORPN), Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) and Vascular Biogenics Ltd. (dba VBL Therapeutics Ltd.) (NASDAQ:VBLX) all took haircuts in IPOs on NASDAQ on Thursday. Bio Blast raised $35…

    Published on 7/31/2014
  • FINANCIAL NEWS: Catalent raises $871.3 million in NYSE IPO

    Catalent Inc. (NYSE:CTLT) raised $871.3 million through the sale of 42.5 million shares at $20.50 in an IPO on the NYSE. The price values the company at $2.4 billion. Earlier this month, the company amended the offering…

    Published on 7/31/2014
  • FINANCIAL NEWS: EyeGate files for IPO

    EyeGate Pharmaceuticals Inc. (Waltham, Mass.) filed to raise up to $28.8 million in an IPO on NASDAQ underwritten by Aegis. Last year, the company reported that transscleral iontophoresis delivery of EGP-437 met the …

    Published on 7/31/2014
  • FINANCIAL NEWS: FDA extends review for AZ's olaparib

    AstraZeneca plc (LSE:AZN; NYSE:AZN) disclosed in its 2Q14 financial results on Thursday that FDA extended the PDUFA date by three months for cancer product olaparib. The PDUFA date is now Jan. 3, 2015; the previous date…

    Published on 7/31/2014
  • FINANCIAL NEWS: Teva reports 2Q14 earnings, raises EPS guidance

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported 2Q14 earnings and raised its 2014 EPS guidance on Thursday. The specialty pharma and generics company reported non-GAAP diluted EPS of $1.23, beating by a penny …

    Published on 7/31/2014
  • FINANCIAL NEWS: Valeant falls on lowered guidance

    Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX) fell $8.44 to $117.39 in New York and C$9.50 to C$127.92 in Toronto after reporting 2Q14 financial results on Thursday and lowering its full-year EPS and …

    Published on 7/31/2014
  • FINANCIAL NEWS: Venrock closes $450M seventh fund

    Venrock closed its seventh fund with $450 million. The firm, which invests in public and private healthcare and technology companies, closed its sixth fund in 2010 with $350 million. Venrock's current healthcare …

    Published on 7/31/2014
  • FINANCIAL NEWS: Amgen up on 2Q14 earnings, workforce cuts

    Amgen Inc. (NASDAQ:AMGN) jumped as much as $7.93 on Wednesday -- hitting an all-time high of $131.24 -- before closing the day up $6.70 to $130.01 after reporting 2Q14 financial results late Tuesday that beat the Street…

    Published on 7/30/2014
  • FINANCIAL NEWS: Epic Sciences raises $30 million in series C

    Cancer molecular diagnostic company Epic Sciences Inc. (La Jolla, Calif.) raised $30 million in a series C round from new investors RusnanoMedInvest and Arcus Ventures, along with existing investors Domain Associates; …

    Published on 7/30/2014
  • FINANCIAL NEWS: Hospira beats Street, plans EPO biosimilar submission

    Hospira Inc. (NYSE:HSP) gained $4.31 to $56.21 on Wednesday after reporting 2Q14 financial results that beat the Street. Adjusted diluted EPS for the quarter was $0.72, beating the Street's $0.57 estimate and up from $0…

    Published on 7/30/2014
  • FINANCIAL NEWS: TherapeuticsMD raises $40.2 million in follow-on

    Women's healthcare company TherapeuticsMD Inc. (NYSE:TXMD) raised $40.2 million through the sale of 8.6 million shares at $4.67 in a follow-on underwritten by Goldman Sachs and Noble Capital Markets. TherapeuticsMD …

    Published on 7/30/2014
  • FINANCIAL NEWS: Accelerator secures $51.1 million, expands to NYC

    Seattle-based biotech incubator Accelerator Corp. secured $51.1 million for Accelerator IV and expanded its operations to New York City. Earlier this year, Accelerator said it planned to set up shop in New York and was …

    Published on 7/29/2014
  • FINANCIAL NEWS: ContraFect raises $36 million in bumped-up IPO

    ContraFect Corp. (NASDAQ:CFRXU) was up $0.45 to $6.45 on its first day of trading Tuesday after raising $36 million through the sale of 6 million units at $6 in an IPO underwritten by Maxim Group. The price values …

    Published on 7/29/2014
  • FINANCIAL NEWS: Merck CEO not interested in inversion deals

    Merck & Co. Inc. (NYSE:MRK) is not interested in pursuing deals "solely or primarily for the specific purpose of tax inversion," said CEO and Chairman Kenneth Frazier during a conference call to discuss the pharma's …

    Published on 7/29/2014
  • FINANCIAL NEWS: Pfizer provides biosimilar details, beats the Street in 2Q

    Pfizer Inc. (NYSE:PFE) disclosed details of its pipeline of five biosimilars during a conference call with analysts to discuss 2Q14 financial results. This half, the pharma expects to start Phase III testing of …

    Published on 7/29/2014
  • FINANCIAL NEWS: Pharmacyclics jumps following Imbruvica approval

    Pharmacyclics Inc. (NASDAQ:PCYC) jumped $16.25 (15%) to $124.75 on Tuesday, adding $1.2 billion in market cap for a valuation of $9.4 billion. The move comes after FDA granted full approval to Imbruvica ibrutinib from …

    Published on 7/29/2014
  • FINANCIAL NEWS: Proteus raises $52 million in second close of G round

    Proteus Digital Health Inc. (Redwood City, Calif.) raised $52 million from undisclosed institutional investors in the second close of a series G round, bringing the total raised in the round to $172 million. The company…

    Published on 7/29/2014
  • FINANCIAL NEWS: Qiagen beats Street, launches $100M repurchase plan

    Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) reported 2Q14 financial results late Tuesday that beat the Street and launched a new $100 million share repurchase program. The sample and assay technology supplier reported 2Q14 …

    Published on 7/29/2014
  • FINANCIAL NEWS: Schulman joins Polaris Partners

    Amy Schulman, former general counsel and EVP at Pfizer Inc. (NYSE:PFE), joined Polaris Partners as a venture partner. Schulman also became CEO of Polaris portfolio company Arsia Therapeutics Inc. (Waltham, Mass.), which…

    Published on 7/29/2014
  • FINANCIAL NEWS: TherapeuticsMD proposes $40 million follow-on

    Women's health company TherapeuticsMD Inc. (NYSE-M:TXMD) proposed late Tuesday to raise $40 million in a follow-on underwritten by Goldman Sachs and Noble Capital Markets. TherapeuticsMD is developing a pipeline of …

    Published on 7/29/2014
  • FINANCIAL NEWS: UTHR gains as earnings top Street

    United Therapeutics Corp. (NASDAQ:UTHR) gained $7.36 to $98.21 on Tuesday after reporting 2Q14 financial results that beat the Street. Diluted GAAP EPS in the quarter was $2.10, beating the Street's $1.75 estimate and …

    Published on 7/29/2014
  • FINANCIAL NEWS: Emulate raises $12 million in series A

    The Wyss Institute for Biologically Inspired Engineering at Harvard University spun out its organs-on-chips technology into newco Emulate Inc. (Cambridge, Mass.), which raised $12 million in a series A round led by …

    Published on 7/28/2014
  • FINANCIAL NEWS: PaxVax secures up to $62M, acquires typhoid vaccine

    Vaccine company PaxVax Inc. (Redwood City, Calif.) secured up to $62 million comprising up to $50 million in debt from Pharmakon Advisors and $12 million in an extension of a series B round from undisclosed existing and…

    Published on 7/28/2014
  • FINANCIAL NEWS: T2 amends IPO

    Diagnostics company T2 Biosystems Inc. (Lexington, Mass.) amended its IPO on NASDAQ and now plans to sell 4 million shares at $15-$17. At the $16 midpoint, the company would raise $64 million and be valued at $288.4 …

    Published on 7/28/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993